TransMedics (TMDX) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

For the quarter ended December 2024, TransMedics (TMDX) reported revenue of $121.62 million, up 49.8% over the same period last year. EPS came in at $0.19, compared to $0.12 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $110.38 million, representing a surprise of +10.19%. The company delivered an EPS surprise of +5.56%, with the consensus EPS estimate being $0.18.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.Here is how TransMedics performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Geographic Revenues- All other countries: $3.89 million versus $3 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +10.7% change. Geographic Revenues- United States: $116.65 million compared to the $108.16 million average estimate based on four analysts. The reported number represents a change of +55.1% year over year. Net revenue by OCS product- OCS Lung net revenue: $3.42 million compared to the $3.83 million average estimate based on four analysts. The reported number represents a change of +6.8% year over year. Net revenue by OCS product- OCS Liver net revenue: $88.98 million versus the four-analyst average estimate of $76.93 million. The reported number represents a year-over-year change of +64.3%. Net revenue by OCS product- OCS Heart net revenue: $28.14 million versus $28.81 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +35.2% change. View all Key Company Metrics for TransMedics here>>>Shares of TransMedics have returned +12.6% over the past month versus the Zacks S&P 500 composite's -2.2% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.5 Stocks Set to DoubleEach was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2024. While not all picks can be winners, previous recommendations have soared +143.0%, +175.9%, +498.3% and +673.0%.Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.Today, See These 5 Potential Home Runs >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report TransMedics Group, Inc. (TMDX): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks